Mumbai: Glenmark Specialty S.A. and global oncology company BeiGene have announced an exclusive marketing and distribution agreement. Through this collaboration, Glenmark will register and commercialise BeiGene’s cancer drugs, Tislelizumab and Zanubrutinib, in India.
With 900,000 lives being claimed by cancer per year in India, this partnership is expected to immensely help low- and middle-income countries with increasing cancer burden. India ranks third in blood cancer cases globally, and the cases are projected to rise to 2.08 million by 2040, a 57.5% increase from 2020.
Alok Malik, President and Business Head of India Formulations at Glenmark Pharmaceuticals Limited said, “The inclusion of Tislelizumab and Zanubrutinib in our oncology portfolio highlights our dedication to cancer patients and our mission to provide access to novel therapies across the country.”
